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ABSTRACT 
An appropriately designed drug delivery system can be a major step towards solving these two problems. This techniq ue for the drug   
administration is termed as ‘sustained release’ or ‘controlled release.  Drugs  with  dosage  not  exceeding  125mg  –  325mg  are  more  suited  
as  extended  release  products in order to limit the size of the delivery system.   In  the  case  of  soluble  matrix  the  matrix  swells  or  dissolves.  
These matrices then undergo surface erosion with little or no bulk erosion. Divalproex sodium dissociates to the valproate io n in the 
gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. One of its most important 
characteristics is the high gelation velocity and viscosity, which has a significant effect on the release kinetics of the incorporated drug. It was 
proven that HPMC at high concentration promoted the drug release approaching to a zero-order release kinetic because of its gelation 
properties 
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New  and  more  sophisticated  sustained  release  drug  
delivery  systems  are  constantly  being  developed  and  
tested.  Successful  fabrication  of  sustained  release  
products  is  usually  difficult  and  involves  consideration  of  
the physicochemical properties of the drug, pharmacokinetic 
behaviour  of the drug, and route of administration, diseased 
state to be treated  and most importantly  placement  of  the  
drug in  a  dosage  form  that  will  provide  the  desired  
temporal  and  spatial  delivery  pattern  for  the drug.1-3 
There  are  literally  dozens  of  names  associated  with  
sustained  release  products  such  as  continuous  release,  
controlled  release,  delayed  release,  delayed  action,  depot,  
extended  action,  gradual  release,  long  acting,  long  lasting,  
long‐term  release,  prolonged  release,  repository  retard,  
slow  acting,  slow  release,  time  coat,  sustained  release,  
sustained  action,  timed  disintegration,  timed  release etc.  
Spatial  placement  relates  to  the  targeting  of  the  drug  to  
a  specific  organ or tissue while temporal delivery refers to 
controlling the rate  of  the drug  delivery  to  the  target  
tissue. An appropriately designed drug delivery system can 
be a major step towards solving these two problems. This 
technique for the drug   administration is termed as 
‘sustained release’ or ‘controlled release.  Drugs  with  dosage  
not  exceeding  125mg  –  325mg  are  more  suited  as  
extended  release  products in order to limit the size of the 
delivery system.   In  the  case  of  soluble  matrix  the  matrix  
swells  or  dissolves.  These matrices then undergo surface 
erosion with little or no bulk erosion.4-6 The  surface  area  of  
the  matrix  decreases  with  time,  with  a  concomitant 
decrease in drug release. The diffusion depends on the 
solubility of the drug in the polymer. The drug release 
mechanism  across  the  membrane  involves  diffusion  of  
water  through  the  membrane to the inside of the core, 
dissolution of the drug and then  diffusion of the drug into 
the surrounding fluid.  In reservoir dissolution control 
system the drug particles are coated  or  encapsulated  by  
one  of  the  several  micro  encapsulation  techniques  with  
slowly  dissolving  materials  like  cellulose  derivatives, poly 
ethylene glycols, waxes etc., the resulting reservoirs  may  be  
filled  as  such  in  hard  gelatin  capsules  or  compressed  
into  tablet. 
Divalproex sodium dissociates to the valproate ion in the 
gastrointestinal tract. The mechanisms by which valproate 
exerts its therapeutic effects have not been established. It has 
been suggested  that  its  activity  in  epilepsy  is  related  to  
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increased  brain  concentrations of Gamma Amino Butyric 
Acid (GABA). The absolute  bioavailability  of Divalproate ER  
tablets administered a  single  dose  after  a  meal  was  
approximately  90%  relative  to  intravenous  infusion.  
Formulation  of  Divalproex  sodium  ER  tablets  expected to  
reduce  Divalproex  sodium  ER  is  used  by  patient  for  
treatment  of chronic  epilepsy.  So  reduces  the  frequent  
administration  of  dose  (twice  in  a  day),  avoids  first  pass  
metabolism,  improved  patient  compliance,  maintain  
therapeutic  action  by  administration  of  a  single dose in a 
day. 7   
2. Reasons for developing an sustained release 
formulation 
Reasons for developing an sustained release formulation are 
not limited to improving tolerability and, as a result, 
effectiveness, or to allowing use of longer dosing intervals. 
An additional reason is simply the pharmaceutical industry's 
desire to extend exclusivity rights for their products. In fact, 
it is no surprise that many extended-release formulations are 
introduced at the time exclusivity rights for the immediate-
release product approach the expiration date. Regulatory 
approval for extended-release formulations does not require 
any comparison of efficacy and safety with the immediate-
release product; to the contrary, pharmacokinetic data and, 
at least in the United States, demonstration of superiority 
over placebo in a single trial is generally sufficient for 
marketing approval. This regulatory scenario implies that 
high-quality data on the comparative efficacy and tolerability 
of the extended- and immediate-release forms of most AEDs 
are usually unavailable.8  
3. Bioavailabillity of Divalproex Extendend-Release 
Tablets 
It has been reported that the absolute oral bioavailability of 
divalproex-ER is 89%, while the oral absorption is practically 
100% for divalproex-DR.5 Steady state 24-hour average 
plasma valproate concentration after once-daily 
administration of divalproex-ER was between 81 and 89% 
(fasting and non fasting conditions respectively) of that 
obtained after twice-daily dosing of divalproex-DR.6 A meta-
analysis of divalproex-ER once-daily/divalproex-DR twice-
daily relative bioavailability across five multiple-dose 
studies, under different meal conditions, revealed a mean 
value for AUCss (area under the steady state total plasma 
drug concentration curve) ER/DR ratio of 0.89.9-11 
4. Polymer used for formulation of suatined 
release of divalproex: 
HPMC is the major hydrophilic carrier material used for the 
preparation of oral controlled drug delivery systems. One of 
its most important characteristics is the high gelation 
velocity and viscosity, which has a significant effect on the 
release kinetics of the incorporated drug. It was proven that 
HPMC at high concentration promoted the drug release 
approaching to a zero-order release kinetic because of its 
gelation properties.12 Lactose is widely used as a binder, 
filler-binder, and flow aid in direct compression tableting. 
The particle size of lactose influences parameters like flow; 
in general, a decrease in particle size will decrease the flow 
which is due to the drug/fine particle fraction (14). SiO2 is a 
fine and amorphous powder consisting of particle about 7–
40 nm in size that has been used in the tablet manufacturing 
as a glidant.13 
5. Requirements for formulation of sustained 
release of divalproex: 
Suatined release of divalproex formulation is a unit process 
that may serve one or more of the following function: to 
mask odour or taste; to ease the swallowing of the dosage 
form; to improve mechanical integrity; to enhance product 
identification and elegance; to improve product stability; and 
to modulate the release properties. The benefits of film 
coating more than justify the exposure of the product to the 
rigour of the coating process, during which the tablets (and 
the applied coating) are constantly subjected to mechanical 
stress along with conditions of elevated temperature and 
humidity. Therefore, core must be designed using more 
stringent criteria compared with uncoated dosage form to 
guarantee a product robust enough to withstand the 
additional stress imparted by the film coating process. The 
design of such a substrate has to be considered in term of 
14,15 
1. The ability of the core to withstand the mechanical 
stress of the process.  
2. Maximized adhesion of coating to the tablet surface.  
3. A film coat with uniform thickness. 
6. Preformulation studies of Divalproex Sodium 
pure drug  
6.1 Preparation of standard calibration curve of 
Divalproex Sodium  
10 mg of drug was dissolved in 0.1 N HCl and final volume 
was make up to 100 ml in 100 ml volumetric flask. The 
staock solution concentration was 100 mcg/ml obtained.  It 
was diluted with 0.1 N HCl to obtain solution of  
Concentration range10 to 60 µg/ml. Absorbance of µg/ml 
solution was measured at 250  nm  by using of  Shimadzu 
UV-1601 UV/Vis double beam spectrophotometer and 0.1 N 
HCl as reference standard.16 
6.2Melting point determination 
The Melting point of Divalproex Sodium was determined 
using open capillary method. The capillary filled with drug 
powder was placed in Thiel’s tube containing liquid paraffin. 
The tube was heated and the melting point of the drug 
powder was noted. The average of three values was 
considered as the melting point of drug. 
6.3Drug excipient compatibility study 
The interaction of the drug and the co-formers were carried 
out by FTIR method to know the physiochemical interaction 
occur in the drug and excipient. The drug and co-formers 
were taken in 1:5 ratios and placed in a vial and rubber 
stopper was placed on the vial and sealed properly for 6 
month at 400C±20C/75%RH±5%RH. 
6.4Differential scanning calorimetry  
The DSC of Tabletwasrecorded by differential scanning 
calorimeter equipped with a computerized data station. 
TheDSC measurements were performed on a DSC 60, 
Shimadzu, Japan instrument. Accuratelyweighed sample 
were placed in a sealed aluminum pans before heating under 
nitrogen flow(20ml/min) at a scanning rate of 100c/min. An 
empty aluminum pan was used as a reference.Melting point 
was determined for identification of API and co-crystal 
former. 
 6.5Solubility Studies 
The equilibrium solubility at a room temperature is 
determined by the shake flask method. According to this 
method the compound is added in to a certain medium and 
shaken at a predetermined time, usually 24h or longer. The 
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saturation is confirmed by observation of the presence of un-
dissolved material. Saturation can also be reached if the 
solvent and excess solute is heated and then allowed to cool 
to the given temperature.  
7. Evaluation of Divalproex Sodium powder 
blend17-18  
7.1 Angle of Repose 
The angle of repose of powder was determined by the 
funnelmethod. The accurately 10 gm weighed powder were 
taken ina funnel. The height of the funnel was adjust and the 
powderwas allowed to flow through funnel freely onto the 
surface.The diameter of the powder cone was measured and 
angle ofrepose was calculated using the following equation: 
Tan θ=h/r , Where θ = angle of repose, h = height of thecone, 
r = radius of the cone base. 
7.2Bulk Density 
A quantity of 10 g of powder from each formulation, 
previously lightly shaken to break any agglomerates formed 
was introduced into a 50 ml measuring cylinder. The bulk 
volume and mass of the powder was determined. The bulk 
density was calculated using following formula: 
Bulk density= Weight of granules/ Volume of granules 
7.3Tapped density 
The measuring cylinder containing a known mass of blend 
was tapped for a fixed time. The minimum volume occupied 
in the cylinder and the mass of the blend was measured. The 
tapped density was calculated using the following formula:  
Tapped density= Weight of granules/ Volume of granules 
after 100 tapping 
7.4 Carrs Index 
The simplest way for measurement of free flow of powder is 
compressibility, an indication of the ease with which 
amaterial can be induced to flow is given by Carr¡¦s index 
which is calculated as follows: 
Carr's index (%) = Tapped Density – Bulk Density/Tapped 
DensityX 100 
Where, 
BD = Bulk density 
TD = Tapped density 
6.5 Hausners ratio 
Hausners ratio value is less than 1.25 indicates good flow 
andgreater than 1.5 indicates poor flow property which 
wascalculated by using following formula:  
Hausnre's ratio = Tapped density/ Bulkdensity 
8. Conclusion: 
Divalproex  sodium  ER  tablets  expected to  reduce  
Divalproex  sodium  ER  is  used  by  patient  for  treatment  
of chronic  epilepsy.  So  reduces  the  frequent  
administration  of  dose  (twice  in  a  day),  avoids  first  pass  
metabolism,  improved  patient  compliance,  maintain  
therapeutic  action  by  administration  of  a  single dose in a 
day. Suatined release of divalproex formulation is a unit 
process that may serve one or more of the following 
function: to mask odour or taste; to ease the swallowing of 
the dosage form; to improve mechanical integrity; to 
enhance product identification and elegance; to improve 
product stability; and to modulate the release properties 
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